Stock TORNTPHARM TORRENT PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Torrent Pharmaceuticals Limited NSE India S.E.

Equities

TORNTPHARM

INE685A01028

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:49 2024-04-26 am EDT 		5-day change 1st Jan Change
2,691 INR -0.12% Intraday chart for Torrent Pharmaceuticals Limited +5.97% +16.72%
Apr. 08 Torrent Pharmaceuticals Limited Receives an Order Passed Under Section 73 of the Goods and Service Act, 2017, Imposing A Penalty of INR 388,809.60 CI
Apr. 01 Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 330,355 333,623 430,029 473,197 520,309 910,571 - -
Enterprise Value (EV) 1 366,505 387,633 458,139 508,027 566,719 947,733 935,831 920,943
P/E ratio 75.7 x 32.6 x 34.3 x 60.9 x 57.4 x 56.1 x 44.3 x 35.7 x
Yield 0.87% 0.86% 1.38% 1.18% 1.43% 0.8% 0.9% 0.98%
Capitalization / Revenue 4.31 x 4.2 x 5.37 x 5.56 x 5.41 x 8.42 x 7.47 x 6.63 x
EV / Revenue 4.78 x 4.88 x 5.72 x 5.97 x 5.89 x 8.76 x 7.67 x 6.71 x
EV / EBITDA 18.5 x 17.9 x 18.4 x 20.9 x 19.9 x 28.1 x 23.9 x 20.3 x
EV / FCF 32.3 x 39.3 x 27.3 x 31.8 x 31.6 x 43.2 x 38.7 x 32.6 x
FCF Yield 3.1% 2.54% 3.66% 3.15% 3.17% 2.32% 2.58% 3.07%
Price to Book 6.99 x 6.92 x 7.4 x 7.95 x 8.4 x 12.7 x 10.9 x 9.1 x
Nbr of stocks (in thousands) 338,444 338,445 338,445 338,445 338,445 338,445 - -
Reference price 2 976.1 985.8 1,271 1,398 1,537 2,690 2,690 2,690
Announcement Date 5/20/19 5/26/20 5/18/21 5/25/22 5/30/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 76,730 79,390 80,050 85,080 96,200 108,151 121,959 137,315
EBITDA 1 19,840 21,700 24,850 24,310 28,420 33,777 39,156 45,355
EBIT 1 13,660 15,160 18,270 17,690 21,350 25,730 30,773 36,743
Operating Margin 17.8% 19.1% 22.82% 20.79% 22.19% 23.79% 25.23% 26.76%
Earnings before Tax (EBT) 1 5,620 11,870 15,260 12,260 18,470 23,149 29,054 35,784
Net income 1 4,360 10,250 12,520 7,770 12,450 16,431 20,552 25,454
Net margin 5.68% 12.91% 15.64% 9.13% 12.94% 15.19% 16.85% 18.54%
EPS 2 12.89 30.28 36.99 22.96 26.79 48.00 60.74 75.29
Free Cash Flow 1 11,352 9,860 16,760 16,000 17,940 21,949 24,181 28,269
FCF margin 14.8% 12.42% 20.94% 18.81% 18.65% 20.29% 19.83% 20.59%
FCF Conversion (EBITDA) 57.22% 45.44% 67.44% 65.82% 63.12% 64.98% 61.75% 62.33%
FCF Conversion (Net income) 260.38% 96.2% 133.87% 205.92% 144.1% 133.58% 117.65% 111.06%
Dividend per Share 2 8.500 8.500 17.50 16.50 22.00 21.53 24.13 26.46
Announcement Date 5/20/19 5/26/20 5/18/21 5/25/22 5/30/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 19,950 19,370 21,340 21,370 21,080 21,310 23,470 22,910 24,910 24,910 25,910 26,329 27,505 27,836 29,472
EBITDA 1 6,070 5,820 6,770 6,600 5,380 5,610 7,120 6,790 7,240 7,270 7,910 8,124 8,597 8,895 -
EBIT 1 4,400 4,170 5,120 4,920 3,710 3,990 5,570 5,160 5,310 5,310 6,000 6,087 6,507 6,782 7,165
Operating Margin 22.06% 21.53% 23.99% 23.02% 17.6% 18.72% 23.73% 22.52% 21.32% 21.32% 23.16% 23.12% 23.66% 24.37% 24.31%
Earnings before Tax (EBT) 1 3,570 3,830 4,840 4,720 3,570 -870 5,320 4,630 4,190 4,330 5,310 5,592 6,014 6,426 -
Net income 1 2,970 3,240 3,300 3,160 2,490 -1,180 3,540 3,120 2,830 2,870 3,780 3,892 4,173 4,570 -
Net margin 14.89% 16.73% 15.46% 14.79% 11.81% -5.54% 15.08% 13.62% 11.36% 11.52% 14.59% 14.78% 15.17% 16.42% -
EPS 2 8.760 9.580 9.765 9.315 7.375 -3.490 20.90 9.220 8.360 8.480 11.18 11.43 12.51 13.23 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/8/21 5/18/21 7/27/21 10/26/21 1/25/22 5/25/22 7/29/22 10/21/22 1/25/23 5/30/23 8/7/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 36,150 54,010 28,110 34,830 46,410 37,163 25,261 10,372
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.822 x 2.489 x 1.131 x 1.433 x 1.633 x 1.1 x 0.6451 x 0.2287 x
Free Cash Flow 1 11,353 9,860 16,760 16,000 17,940 21,949 24,181 28,269
ROE (net income / shareholders' equity) 15.4% 21.5% 23.5% 13.2% 20.5% 24.2% 26.9% 28.4%
ROA (Net income/ Total Assets) 5.06% 7.28% 8.92% 5.72% 8.86% 11.2% 13.3% 15.4%
Assets 1 86,166 140,795 140,425 135,875 140,560 147,350 154,743 165,299
Book Value Per Share 2 140.0 142.0 172.0 176.0 183.0 213.0 247.0 296.0
Cash Flow per Share 2 53.20 41.10 59.40 53.30 51.00 63.60 69.10 78.60
Capex 1 6,628 4,060 3,350 2,030 5,740 3,488 3,477 3,575
Capex / Sales 8.64% 5.11% 4.18% 2.39% 5.97% 3.22% 2.85% 2.6%
Announcement Date 5/20/19 5/26/20 5/18/21 5/25/22 5/30/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Torrent Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
2,690 INR
Average target price
2,729 INR
Spread / Average Target
+1.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TORNTPHARM Stock
  4. TORNTPHARM Stock
  5. Financials Torrent Pharmaceuticals Limited